What is HC Wainwright’s Estimate for GRCE FY2025 Earnings?

Grace Therapeutics, Inc. (NASDAQ:GRCE) – HC Wainwright issued their FY2025 EPS estimates for shares of Grace Therapeutics in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst O. Livnat expects that the company will earn ($1.14) per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Grace Therapeutics’ current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Grace Therapeutics’ Q4 2025 earnings at ($0.25) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.69) EPS, FY2028 earnings at $0.26 EPS and FY2029 earnings at $1.68 EPS.

Grace Therapeutics Stock Performance

Shares of Grace Therapeutics stock opened at $3.34 on Thursday. The company has a market cap of $33.87 million, a P/E ratio of -2.88 and a beta of 1.36. The stock’s 50 day moving average price is $3.66. Grace Therapeutics has a 1-year low of $2.13 and a 1-year high of $4.97.

Grace Therapeutics (NASDAQ:GRCE) last issued its earnings results on Thursday, February 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01.

About Grace Therapeutics

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.